Search

Your search keyword '"JIJUAN YANG"' showing total 5 results
Start Over Author "JIJUAN YANG" Language english
5 results on '"JIJUAN YANG"'

1. Upregulation of microRNA‐762 suppresses the expression of GIPC3 in systemic lupus erythematosus and neuropsychiatric systemic lupus erythematosus

Author

Jijuan Yang, Chun Li, Shuhong Chi, Hongliang Wei, Wenqing Du, and Qikuan Hu

Subjects
GIPC3, microRNA‐762, neuropsychiatric systemic lupus erythematosus (NPSLE), systemic lupus erythematosus (SLE), Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background Systemic lupus erythematosus (SLE), especially neuropsychiatric SLE (NPSLE), is a complex systemic autoimmune disease, characterized by variable course and multiple organ dysfunction. Our study aimed to identify crucial microRNA (miRNAs) in SLE and NPSLE. Methods Totally 12 cases of serum specimens were collected from General Hospital of Ningxia Medical University (SLE = 4, NPSLE = 4, control = 4). After miRNA sequencing, differential expression analysis, miRNA target prediction, and miRNA‐messenger RNA (mRNA) regulatory network construction were performed to identify the hub miRNAs. The expression of target gene was determined by quantitative reverse transcription‐polymerase chain reaction and Western blot. Results There were 79 and 59 differentially expressed miRNAs (DEmiRNAs) in NPSLE versus Control, and SLE versus Control, respectively. Among 35 overlapped DEmiRNAs, 5 upregulated miRNAs' (hsa‐miR‐762, hsa‐miR‐4270, hsa‐miR‐3663‐3p, hsa‐miR‐4778‐5p, and hsa‐miR‐4516) target genes were supported by at least six databases. The miRNA‐mRNA network indicated that core miRNA hsa‐miR‐762 regulated 1270 target genes. MiR‐762 was significantly upregulated in SLE and NPSLE, and over expression of miR‐762 significantly suppressed GIPC PDZ domain containing family member 3 (GIPC3) expression in SLE and NPSLE. Conclusions Upregulation of hub miRNA miR‐762 can suppress the expression of GIPC3 in both SLE and NPSLE samples, which is probably involved in the development of SLE and NPSLE. Meanwhile, along with the development from SLE to NPSLE, miR‐762 exhibits higher expression.

Published
2022
Full Text
View/download PDF

2. Effect of the interference with DRP1 expression on the biological characteristics of glioma stem cells

Author

Huimei Cao, Qikuan Hu, Hong Tao, Linna Zhang, Wei Gong, and Jijuan Yang

Subjects
0301 basic medicine, Cancer Research, endocrine system, Cell, DRP1, 03 medical and health sciences, 0302 clinical medicine, Immunology and Microbiology (miscellaneous), Glioma, medicine, Oncogene, Chemistry, mitochondrial fission, General Medicine, Articles, Cell cycle, medicine.disease, In vitro, Mitotic inhibitor, Cell biology, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, glioma stem cells, Neuron, Stem cell
Abstract

In the present study, a model of glioma stem cells (GSCs) was established and combined with molecular targeting drugs in order to observe its inhibitory effect on the proliferation and biological characteristics of GSCs, with the aim of providing a potential target for the treatment of glioma. On the basis of a relatively classical induction strategy with neuron induction medium, a large number of GSC-like cells in good condition and globular growth were amplified in vitro, which had the potential to differentiate into neurons, oligodendrocytes and astrocytes/glioma cells. It was observed that the interference with dynamin-related protein 1 expression using Mdivi-1, a mitochondrial mitotic inhibitor, at the optimal concentration, decreased the expression level of stem cell-associated genes, inhibited proliferation and promoted apoptosis in GSCs. The present study provided an experimental basis for a novel strategy of cancer treatment with tumor stem cells as the target.

Published
2021

3. Small molecular compounds efficiently convert human fibroblasts directly into neurons.

Author

JIJUAN YANG, HUIMEI CAO, SHENGNAN GUO, HONG ZHU, HONG TAO, LINNA ZHANG, ZHANGPING CHEN, TAO SUN, SHUHONG CHI, and QIKUAN HU

Subjects
*MOLECULES, *NEURONS, *GLUTAMATE transporters, *SMALL molecules, *MICROTUBULE-associated proteins, *GLUTAMATE receptors, *FIBROBLASTS, *MONOAMINE transporters
Abstract

No effective treatment is currently available for neurodegenerative diseases, and existing pharmacotherapy is inconsistent with severe side effects. Cell replacement therapy is promising for neurodegenerative disease treatment, and the induction of neurons is an unmet need for such therapy. The present study investigated the potential of a combined medium composed of conditioned medium and eight small molecular compounds in reprogramming human foreskin fibroblasts (HFFs) into neurons. HFFs were cultured from foreskin and then induced by small molecules to generate neurons. The results demonstrated that the conditioned medium containing forskolin, RepSox, SP600125, CHIR99021, Go6983, Y‑27632, IXS9 and I‑BET151 effectively induced human fibroblasts to change into neurons in vitro. Following a 30‑day induction, the cells exhibited neuronal properties as determined by morphological and phenotypical alterations. The induced cells exhibited expression of neuronal markers, including class III β‑tubulin, microtubule‑associated protein 2, vesicular glutamate transporter 1 and γ‑aminobutyric acid, accompanied by increased expression of neuronal transcription factors, including neuronal differentiation 1 and achaete‑scute family bHLH transcription factor 1, and decreased expression levels of fibroblast‑specific genes. Furthermore, these cells also exhibited electrophysiological properties of neurons. Notably, the course of cell morphological alterations demonstrated the differentiation of fibroblasts into neurons. The present study provided a novel combination of existing small molecular compounds that efficiently reprogramed human fibroblasts into neurons. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

4. Correlation of Serum Soluble Interleukin-7 Receptor and Anti-C1q Antibody in Patients with Systemic Lupus Erythematosus

Author

Xuemei Wang, Jing Xue, Caixia Zhu, Feng Li, Jijuan Yang, Shuhong Chi, Chen Ji, Yurong Zhang, Lijuan Yang, Haibo Li, Yunxia Yu, Shaolan Zhou, and Xiaoming Liu

Subjects
0301 basic medicine, lcsh:Immunologic diseases. Allergy, Article Subject, Immunology, Lupus nephritis, Serology, Correlation, 03 medical and health sciences, 0302 clinical medicine, Immunology and Microbiology (miscellaneous), immune system diseases, Immunology and Allergy, Medicine, In patient, Receptor, Interleukin-7 receptor, skin and connective tissue diseases, 030203 arthritis & rheumatology, biology, business.industry, Autoantibody, medicine.disease, female genital diseases and pregnancy complications, 030104 developmental biology, biology.protein, Antibody, business, lcsh:RC581-607, Research Article
Abstract

Background.Serum concentrations of soluble interleukin-7 receptor (sIL-7R) and anti-C1q antibody have recently been identified as unique serological markers for lupus nephritis (LN) in patients with systemic lupus erythematosus (SLE). In this study, we evaluated the correlation of serum sIL-7R and anti-C1q in SLE patients.Methods.Sera from 134 patients with SLE and 84 healthy cohorts were tested for levels of sIL-7R and anti-C1q antibodies in terms of ELISA. Correlations of the sIL-7R and anti-C1q autoantibodies were evaluated.Results.The serum concentrations of sIL-7R and anti-C1q antibodies were significantly higher in SLE patients and LN patients in comparison with healthy individuals/controls and SLE patients with non-LN, respectively. In addition, both sIL-7R and anti-C1q concentrations were found to significantly correlate with the SLE disease activity as evaluated by SLEDAI scores. Interestingly, the serum sIL-7R concentration was strongly correlated with the level of anti-C1q antibodies (r=0.2871,p=0.0008) but not statistically correlated with other serological markers, including the anti-dsDNA and complements C3 and C4 concentrations in SLE patients.Conclusion.Both serum sIL-7R and anti-C1q antibodies were strongly associated with disease activity and LN in SLE patients, suggesting that they may be reliable serological markers for identification of SLE patients with active diseases and LN.

Published
2016

5. Antibodies against C1q Are a Valuable Serological Marker for Identification of Systemic Lupus Erythematosus Patients with Active Lupus Nephritis

Author

Shuhong Chi, Xiaoming Liu, Juan Shi, Yunxia Yu, Lijuan Yang, Jijuan Yang, and Yurong Zhang

Subjects
Adult, Male, Article Subject, Adolescent, Clinical Biochemistry, Lupus nephritis, Disease, Serology, immune system diseases, Genetics, Medicine, Humans, In patient, Serologic Tests, skin and connective tissue diseases, Molecular Biology, Aged, Autoantibodies, lcsh:R5-920, biology, business.industry, Complement C1q, Biochemistry (medical), Autoantibody, Case-control study, General Medicine, Middle Aged, medicine.disease, Lupus Nephritis, Case-Control Studies, Immunology, biology.protein, Female, Antibody, lcsh:Medicine (General), business, Biomarkers, Anti-SSA/Ro autoantibodies, Research Article
Abstract

Objective. An early diagnosis of lupus nephritis (LN) has an important clinical implication in guiding treatments of systemic lupus erythematosus (SLE) in clinical settings. In this study, the diagnostic values of circulating autoantibodies to C1q alone or in combination with other markers for accessing active SLE and LN were evaluated.Methods. The diagnostic value of anti-C1q autoantibodies for identification of patients with active SLE disease and LN was evaluated by analyzing the level of anti-C1q antibodies in sera from 95 SLE patients, 40 non-SLE patients, and 34 healthy cohorts.Results. The prevalence of anti-C1q antibodies was significantly higher in patients with SLE (50/95, 52.6%), active SLE (40/51, 78.4%), and LN (30/35, 85.7%) in comparison with non-SLE patient controls, patients with inactive SLE, and non-LN, respectively. A combination of anti-C1q with anti-dsDNA and/or levels of complements C3 and C4 exhibited an increased specificity but a decreased sensitivity for identification of patients with active SLE and LN diseases relative to each of these markers alone.Conclusion. Anti-C1q antibodies were strongly associated with disease activity and LN in SLE patients, suggesting that it may be a reliable serological marker for identification of SLE patients with active LN and active SLE disease.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results